PAZ Pharma Zen

[winner69]

The same could be said for the following shares listed on NZX;
AGL,AIR,AOF,ARB,ARV,ATM,BAI,BLT,BRW,CVT,ERD,GFI,GX H,IKE,KMD,MEE,MHJ.MOV,MPG,NTL,NZK,OCA,PEB,RAK,RYM, SML and TRU.
What PAZ is trying to achieve remains on course.Just a great number of set backs have held them back.
Their existing factory at Port Hill Road is achieving great production results.New factory at Rolleston, which is state of the art is finished,and will slowly be brought into production.Turnover has increased in the past 6 years from $7mil to $29m last year.
Further hard work and a few things going PAZ's way should see PAZ having an exciting future.

Further hard work and a few things going PAZ's way should see PAZ having an exciting future

The same could be said for the following shares listed on NZX; AGL,AIR,AOF,ARB,ARV,ATM,BAI,BLT,BRW,CVT,ERD,GFI,GX H, IKE,KMD,MEE,MHJ.MOV,MPG,NTL,NZK,OCA,PEB,RAK,RYM,SM L and TRU.

Exciting times ahead

sorry Percy …just getting in before Baa_Baa

[percy]

Further hard work and a few things going PAZ's way should see PAZ having an exciting future

The same could be said for the following shares listed on NZX; AGL,AIR,AOF,ARB,ARV,ATM,BAI,BLT,BRW,CVT,ERD,GFI,GX H, IKE,KMD,MEE,MHJ.MOV,MPG,NTL,NZK,OCA,PEB,RAK,RYM,SM L and TRU.

Exciting times ahead

sorry Percy …just getting in before Baa_Baa

Off course I missed FBU,MFB ,WCO and WHS .
Yes the next couple of years should see some on the list do well,while others will remain serial under performers.
Perhaps PAZ will out perform them all.??...

[Joshuatree]

The elephant in the room is that this was spruiked massively, sucking in multiple investors (some of whom cannot or could not, or should not afford to be in the position they are now in) who are now down massive multiples and it might take years, if ever, to get back to the +$1.00's if it ever does. Well done the spruickers, you got the audience invested, but now you should hold your head in shame hoping it all comes true some day, but will it, and when?

Influence imo should be be carefully executed, Asimov said, "prognostication is all too often scorn to begin with and ridicule to end with". Well, now deal with the ridicule, PAZ has lost many investors untold $, which some might not be in a position to have lost. Shame on the spruickers.

Shame ,big shame for the spruikers of OCA especially the one that fell silent after promoting ,influencing ( follow me)and pumping OCA for years,big shame.Blahbabbaa as well.
If your post was aimed at Percy well get a life,he is one of the few posters I can value and trust on here for his enthusiasm,honesty and generous sharing of his investments and ideas.

[Walter]

Another article here
PharmaZen finds cash in ‘trash’ by-products (farmersweekly.co.nz)

[Bluebell]

PAZ's UK based director Dr.Wayne Burt remains "close" to Cibus.

If that were really the case then one would have thought the Chairman would know why they weren't exercising the position on the board...maybe they've had enough of the old boys club

[iceman]

If that were really the case then one would have thought the Chairman would know why they weren't exercising the position on the board...maybe they've had enough of the old boys club

They have never really shown any real interest in the Board position. My understanding always has been that their input was more on the marketing side with their contacts and partners in the UK/Europe. Maybe they just feel little benefit from a Board position, both for PAZ and themselves !

[iceman]

The elephant in the room is that this was spruiked massively, sucking in multiple investors (some of whom cannot or could not, or should not afford to be in the position they are now in) who are now down massive multiples and it might take years, if ever, to get back to the +$1.00's if it ever does. Well done the spruickers, you got the audience invested, but now you should hold your head in shame hoping it all comes true some day, but will it, and when?

Influence imo should be be carefully executed, Asimov said, "prognostication is all too often scorn to begin with and ridicule to end with". Well, now deal with the ridicule, PAZ has lost many investors untold $, which some might not be in a position to have lost. Shame on the spruickers.

The "Elephant in the room", AKA Mr OCA, has spoken 🤣🤣🤣

[percy]

Does any one have access to this NBR article and can share it with us.?


NBR

YOUR BUSINESS



Waitaki Biosciences’ heavy capital investment starts to pay off



The nutraceutical pioneer is launching its own branded range into China after boosting manufacturing capacity.

[percy]

Another article here
PharmaZen finds cash in ‘trash’ by-products (farmersweekly.co.nz)

Following on from the Farmers Weekly article there has been further positive articles,one in Womans Day on AiOra brand Ambassador Boh Runga,and another in NBR.
However, the stand out to me was the one in NZSA's write up on PAZ's AGM, where the writer declared he bought a small holding the day after the meeting.!!..lol

[Sideshow Bob]

HY 2024 Results

https://prod-trade.usx.co.nz/api/fil...1c231d90cf.pdf

Strong Sales Growth ContinuesChristchurch biotechnology company PharmaZen (USX.PAZ) today reports first-half sales of$13.7m and Underlying EBITDA of $620k.

As presented at the Annual Shareholder Meeting demand across all sections of the businesscontinues to be strong with sales up over 25% on same period in 2023.The first six months of the year are typically the most challenging and this year was madeparticularly difficult with supply issues for our krill extraction business as a result of our krillsupply partner’s delays with their new boat.

The fact that sales are up with the extraction plantthat produces the krill products operating at very low levels reflects the strength of our otherranges.Underlying EBITDA while up on prior year first half was off a low base and reflects a combinationof increased indirect costs and lower than optimal utilisation.

PharmaZen Chair Ken Fergus said: “Given supply issues with krill the sales growth is extremelypleasing. The EBITDA falls short of where we wanted it to be and it’s a consequence of multiplefactors, including cost pressures from insurance and significantly increased marketing investmentwith the branded products – particularly the August pet launch.

However, the main impact has beenfrom utilisation. Profitability is heavily dependent on utilisation and volume - while up on the priorperiod - is not at the levels that we know we can now achieve.”The Tawhiri factory at Rolleston now has the key country listings in place, and we have started tomove products and production out to this new plant. Processing from this plant will accelerate overthe coming months, further increasing our capacity.

OutlookThe increase in capacity the company has put in place and the continuing strong demand we are seeingfrom our customers puts the company in a great position to achieve increased sales and profitability inthe second half and into the next financial year and beyond.

Ken Fergus commented that “Our challengesare around maintaining our high standards of product quality and carefully managing capex as we getTawhiri rolling. We are very excited by the potential of the new opportunities we see in our markets andare confident that we have the right people and processes in place to benefit from these newopportunities”.